Abstract The incidence of diabetes mellitus (DM) is increasing worldwide, and both type 1 as well as type 2 DM patients are at high risk of developing diabetic nephropathy (DN). Although the effects of DM and DN have been well documented for low molecular weight proteins and albumin, there is limited information regarding the changes in the clearance of higher molecular weight proteins, including monoclonal antibodies (mAbs) and IgG, an antibody isotype. This review compiles the available literature describing the effects of DM and DN on the pharmacokinetics and pharmacodynamics of IgG and mAbs and the potential mechanisms underlying the effects of DM and DN on IgG/mAb renal and catabolic clearances. This review also highlights the role of the neonatal Fc receptor (FcRn) and endocytic receptors (megalin and cubilin) and the influence of cytokines on renal function and expression/function of these proteins.
Introduction
Diabetes mellitus (DM) is a complex chronic metabolic disturbance of carbohydrate metabolism characterized by fasting and/or postprandial hyperglycemia [1] . DM has been defined as a group of diseases, rather than a single homogenous syndrome, caused by altered efficiency in the synthesis and release of insulin, resistance to the action of insulin, or both [1, 2] . Long-term occurrence of diabetes can cause further complications involving cardiovascular diseases, damage to blood vessels (angiopathy), and nerve damage (neuropathy). Other complications include damage to the renal system (nephropathy) and lower limb amputation due to impaired circulation. Diabetes has also been associated with dysfunction of various metabolic pathways and is often correlated with significant hypertension and dyslipidemia [1, 3] .
Significant effects of DM/ diabetic nephropathy (DN) on small molecules have been reported, but there are only a few studies that have evaluated the impact of DM/DN on the pharmacokinetics (PK) of antibodies [4] . Although the prevalence of microalbuminuria and macroalbuminuria is significant with type 2 diabetes mellitus (T2DM), only a limited number of studies have evaluated the alteration in renal elimination and urinary concentrations of proteins and macromolecules such as IgG [5, 6] . The preclinical and clinical evidence for changes in protein clearance, including that of monoclonal antibodies, in DM and DM/DN will be presented in this review, as well the potential mechanisms underlying these changes. subsequent increase in blood and urine glucose levels. This leads to the classical symptoms of polyuria, polydipsia, polyphagia, and weight loss [8] . T1DM occurs as an acute metabolic dysfunction with sudden onset in children, adolescents, or young adults. If untreated, it can lead to diabetic ketoacidosis and nonketotic hyperosmolar coma. Although the onset of T1DM is observed mostly before the age of 30, in recent years, some older individuals with type 2 diabetes mellitus have been observed to develop immune system disorders, leading to the simultaneous development of T1DM. Worldwide, T1DM accounts for 5-10 % of all patients with DM [9] . T2DM (formerly called non-insulin-dependent or adult-onset) is the more common type of diabetes, constituting 90-95 % of cases. T2DM manifests as insulin resistance which renders cells insensitive to the presence of glucose. This mostly occurs during middle age; however, childhood obesity is leading to increased prevalence in teenagers [9] [10] [11] .
The various complications of diabetes including retinopathy, amputation after trauma, increased risk of atherosclerotic vascular disease, DN, and end-stage renal disease (ESRD) have made diabetes the major contributor to morbidity and mortality in society [12, 13] . Diabetic nephropathy represents around 17 % of the complications of diabetes and is the major cause of end-stage renal failure (ESRF) in Western societies [14] . Compared to T1DM, a greater percentage of patients with T2DM have complications leading to DN. This can be attributed to the fact that diabetes may have been present for several years before its diagnosis is established. Simultaneous presence of hypertension also increases the prevalence of microalbuminuria in T2DM [1] .
As of 2012, around 21 million people have been diagnosed with diabetes in the USA, with another 8.1 million estimated to be undiagnosed [10] . Globally, in 2010, it was estimated that around 285 million people have been diagnosed with T2DM. It is estimated that the prevalence of T2DM will increase to around 500 million people worldwide by 2030 [11, 15] . The number of patients with diabetes has been increasing due to population growth and adverse social habits, including poor diet choices and decreased physical activity, leading to obesity [11] . In the USA, the total spending for diabetes treatment in 2012 was $245 billion and the expenditure for ESRF was $32.9 billion [16, 17] , indicating significant societal health care impact.
Diabetic Nephropathy
DN represents a major microvascular complication of diabetes and is known to be the leading cause of ESRF [12, 18] . DN is a progressive kidney disease caused by microvascular changes in the kidney glomeruli. It is characterized by increased elimination of serum proteins in the urine (proteinuria) with a subsequent decline in glomerular filtration rate (GFR). The earliest clinical symptom of DN is microalbuminuria (presence of low but significant amount (≥30 mg/day of albumin in the urine)). Without therapeutic intervention, around 80 % of T1DM and 30 % of T2DM patients progress to macroalbuminuria (≥300 mg/day of albumin in the urine) over a period of 10-15 years. This is followed by a gradual decrease in the GFR, with ESRF subsequently occurring in 50 % of T1DM and 20 % of T2DM patients [12, 13] . Commonly, hypertension and poor glycemic control frequently occur before macroalbuminuria occurs, although a small percentage of the diabetic population develops DN despite euglycemic control and normal blood pressure. The progression of DN has been classified into five stages (Table 1) in which a normal renal system proceeds to ESRF mediated by the structural and functional deterioration of the kidney [19, 20] . The earliest structural abnormality observed routinely in diabetic animals, as well as patients, is an increase in the thickness of the glomerular basement membrane (GBM) [21, 22] . Changes in GBM thickness can occur even in the a b s e n c e o f a l b u m i n u r i a [ 2 2 , 2 3 ] . H o w e v e r, a s microalbuminuria persists and becomes more severe, there is a further increase in the GBM thickness, suggesting that there may be an association between protein leakage and progression of GBM thickening [22, 23] .
Recently, it has been demonstrated that the podocytes also play an important role in the proteinuria observed in DM/DN and in the development of glomerulosclerosis [24, 25] . The strategic location of podocytes surrounding the GBM and glomerular capillaries allows the podocytes to significantly contribute to the protein efflux from the glomeruli into the urinary space within Bowman's capsule (Fig. 1) . With early DN, structural alterations in podocytes can lead to widening of the attachment points to the GBM. This initial alteration can also occur without development of microalbuminuria [25] . Moreover, as DN becomes more severe, further damage to podocytes leads to complete detachment from the GBM and excretion into the urine. Focal segmental glomerulosclerosis and membranous nephropathy are associated with podocyte detachment and apoptosis [27, 28] . Podocytes were absent in the urine of healthy controls without albuminuria and chronic kidney failure diabetic patients. However, with microalbuminuria, a significant increase in the amount of podocytes in the urine occurred. The number of podocytes in urine further increased with macroalbuminuria. Other studies have also reported a decrease in the number/density of podocytes per glomerulus with increasing albuminuria. Since podocytes cannot regenerate, compensation for this loss does not occur. Although no direct relationship was observed in amounts of urinary albumin excretion and urinary podocytes, the trend in the data suggested that podocytes can be utilized as an important marker of DN [28] . Furthermore, podocyte-specific protein (nephrin) can be dysregulated in DN, and the decrease in expression may be due to • Hypoalbuminemia and edema
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• Dialysis needed different regulatory factors [29, 30] . Thus, the association between podocyte protein abnormalities and DN may contribute to proteinuria and eventually glomerulosclerosis. The tubulointerstitium accounts for as much as 90 % of kidney volume and changes in the tubulointerstitium in diabetes include thickening of the tubular basement membrane and tubular atrophy. Conventionally, changes due to glomerular injury and podocyte effacement have been described as the primary cause of renal disease progression. Changes in tubulointerstitium have been defined as a secondary reaction to elevated intratubular protein due to glomerular leakage [31, 32] . However, in some cases, tubular injury can also contribute further to glomerular damage which was observed with overexpression of vascular endothelial growth factor (VEGF)-A in transgenic mice [33] . Overexpression of VEGF in the renal tubular system of rats led to tubular cyst formation along with interstitial fibrosis. Although the pathway involving the degeneration of tubules prior to glomerular sclerosis is possible, it is less frequent [34] . No clear correlation has been observed between tubular membrane thickening and renal impairment. On the other hand, significant correlations have been observed between interstitial expansions and magnitude of renal dysfunction and with albuminuria along with mesangial enlargement in both T1DM and T2DM [35] [36] [37] .
Overall, the role of progressive glomerular injury along with changes in the tubulointerstitium in DN can be characterized by the following mechanisms: (a) self-sustained production of pro-inflammatory cytokines and growth factors (such as interferons, interleukins, lymphokines, and tumor necrosis factor) in glomerulus and tubulointerstitium; (b) increased filtered protein in the proximal tubule, leading to local hypoxia and peritubular damage; and (c) post-glomerular ischemia and atrophy due to sustained synthesis and release of vasoactive mediators [34, 35, 37] .
Pharmacokinetics of IgG and Monoclonal Antibodies (mAbs) in DM and DM/DN
Antibodies (also known as immunoglobulins, Igs) are large molecular weight proteins, which are produced by the body's immune system when it detects antigens (bacteria, parasites, and viruses). Igs are classified based on the structure of their heavy chains as IgA, IgD, IgE, IgG, and IgM. IgG comprises around 80 % of the Igs in human serum and is the predominant class of immunoglobulins. All of the approved therapeutic antibodies are IgGs [38, 39] . Interest in the development of novel antibody drugs has been rapidly increasing over the last few decades, with more than 30 antibody products approved by the FDA and more than 100 in clinical development [40] . Although significant effects of DM/DN on small molecules have been reported, there are only a few studies that have evaluated the impact of DM/DN on the PK of mAbs [4] .
Role of FcRn
Convection plays a major role in the movement of mAbs from the vascular compartment to the interstitial fluid, with a very minimal role for diffusion. mAbs present in the blood or interstitial fluid may enter cells via pinocytosis (receptor-mediated endocytosis, fluid-phase endocytosis). This represents an important pathway ( Fig. 2) for antibody internalization into cells, since mAbs binding to the neonatal Fc receptor (FcRn), also known as the Brambell receptor, protects mAbs from intracellular lysosomal degradation, since it results in recycling of mAbs to the plasma and/or interstitial space [39, 41, 42] . However, the protection via FcRn in the lysosome is a saturable process since FcRn is capacity limited (due to its finite expression). Hence, the elimination half-life of mAbs is concentration-dependent due to saturable FcRn binding [39, 41, 43, 44] .
The catabolism of mAbs and endogenous proteins, including albumin and IgG, occurs in various organs including liver, intestine, and tissues containing reticuloendothelial components such as spleen, skin, and muscle [45, 46] ; these organs express FcRn that recycles mAbs [43] . The importance of FcRn has been highlighted in different studies using a FcRn knockout mouse animal model and demonstrating significantly different tissue distribution and concentrations of 111 indium-labeled IgG, as compared to the control animals [47] . In another study, also using a mouse animal model, decreased spleen and renal uptake and increased hepatic uptake of IgG were observed in the absence of FcRn protection [48] . Interestingly, using trend where tissue distribution in FcRn knockout mice was similar to the control animal [49] . These differences would be due to the non-residualizing ability of iodine.
FcRn also plays a significant role in the renal elimination of endogenous proteins (albumin and IgG, Fig. 3 ) and mAbs [50] [51] [52] . The glomerular filtration barrier, which is made up of the fenestrated endothelium, the GBM, and the podocyte slit diaphragm, functions as a charge-and size-selective barrier. Blood is filtered through the glomerular capsule of the nephrons into the proximal convoluted tubule, where water and proteins are reabsorbed. A healthy adult filters roughly 180 L of plasma every 24 h, across the two kidneys. This results in the filtration of more than 7 kg of albumin and 2 kg of IgG in humans [50, 53] . Due to the fluid flow dynamics, significant amounts of serum proteins such as albumin and IgG can enter the GBM and accumulate behind the slit diaphragms of the podocytes; FcRn removes proteins that would otherwise clog the slit diaphragm [50] [51] [52] . The importance of podocyte FcRn is clearly demonstrated in studies where delayed clearance of IgG leads to serum-induced nephritis. Local nephrotoxic damage has been observed in diseases such as systemic lupus erythematosus, in which IgG and immune complexes are deposited at the glomerular barrier [52, 54] .
Filtered plasma proteins are reabsorbed via receptormediated endocytic pathways by renal proximal tubule cells. The proximal tubule cells also express FcRn, and different studies have reported the significant role of FcRn in the uptake of albumin and IgG [55, 56] . Lack of FcRn expression abolished the tubular uptake of albumin and IgG [56, 57] . Such was also the case when normal mice were transplanted with FcRn deficient kidneys. FcRn-deficient mice had significantly higher urinary albumin excretion as compared to control mice. When these FcRn-deficient mice were transplanted with an FcRn-expressing kidney, increased serum levels of albumin along with decreased urinary albumin excretion was observed. On the other hand, minimal urinary excretion of IgG is observed in FcRn-deficient mice, but this increases to normal levels when the mice are transplanted with a single FcRn-expressing kidney. Thus, within the kidneys, FcRn is responsible for reclaiming albumin and restoring it to the systemic circulation. In contrast, the role of renal FcRn in the renal reabsorption and clearance of IgG is not clear [51] . 
Role of Megalin and Cubilin
Although FcRn may play a significant role in the renal tubular reabsorption of albumin and IgG, other endocytic proteins may also play important roles. Many studies have observed uptake of albumin by the proximal tubular cells to be an active process, which also depends on the receptor complex consisting of cubilin and megalin (LPR2) endocytic receptors [58-60, 61•] . Megalin is a large membrane glycoprotein that belongs to the low-density lipoprotein receptor (LDLR) family [60, 61•, 62] . Megalin is internalized with its ligands into endocytic compartments and then recycled to the cell surface [63] . Cubilin originally identified as the intestinal intrinsic factor B12 receptor [64] is a large glycoprotein that lacks a transmembrane and a cytoplasmic domain, so it needs to interact with other membrane proteins, such as megalin for endocytosis. The function of cubilin also depends on amnionless (AMN), a 38-to 50-kDa transmembrane protein [61•] . In the proximal tubule, AMN colocalizes with cubilin and is essential for the trafficking of cubilin to the apical membrane. Megalin and cubilin are expressed in the plasma membrane and are involved in the endocytosis pathway for epithelial cells. [61•, 65] . In renal proximal tubule cells, cubilin forms a two-receptor complex with megalin, with megalin directing internalization of the complex and bound ligands [61•, 65, 66] . Megalin is responsible for the reabsorption of nearly all filtered plasma proteins, in cooperation with cubilin; the complex plays a key role in the uptake of low molecular weight (MW) proteins, the intermediate MW protein albumin, as well as higher MW proteins such as IgG [67, 68] . Megalin-knockout mice develop low MW proteinuria and albuminuria [62, 69] . Based on these findings, FcRn, megalin, and cubilin all contribute to proximal tubular reabsorption, where megalin-cubilin form a protein complex to internalize the protein, which then is taken into the lysosome where it can be broken down or protected via FcRn binding. In case of IgG, renal vascular endothelial FcRn can remove IgG from the circulation into the interstitium, where IgG can be taken up by the tubular cells at their basolateral site, followed by transcytosis into the urine. This would help to provide the underlying tissue the necessary immunity against infectious agents [50, 51] .
Effect of DM/DN on the Pharmacokinetics of IgG and mAbs
Although microalbuminuria and macroalbuminuria occur in T2DM, only a limited number of studies have evaluated the alteration in renal elimination and urinary concentrations of proteins and macromolecules such as IgG [5, 6] . T2DM patients have been reported to have 200-fold higher concentrations of IgG2 in urine [5] , and increased renal elimination and urinary concentrations of IgM and IgG has been reported with T2DM and DN in Pima Indians [6] . In another study, the total clearance of adalimumab in patients with focal segmental glomerulosclerosis was reported to be two-to fivefold higher with disease progression, with non-renal clearance contributing more to the change in total clearance than renal clearance [70•] . Additionally, diabetic co-morbidity in psoriatic patients resulted in a 28.7 % higher oral clearance (CL/F) of ustekinumab [71] . Significant increases in the clearance of 8C2 (a murine monoclonal antibody) have been observed with type 1 DM in streptozotocin-treated mice. These changes were positively correlated with changes in urinary albumin excretion and glomerular filtration rates [72] .
Under normal conditions, only a fraction of proteins of molecular weight >70 kDa are filtered into the tubular lumen. The small percentage of proteins that cross into the lumen undergo tubular reabsorption by the epithelial cells of the proximal tubule. Hence, almost negligible amounts of mAbs are eliminated in the urine [73] . In DM/DN, there is an increase in the urinary elimination of intermediate molecular weight proteins (albumin) and high molecular proteins (mAbs, IgA, IgG). The increased elimination of these proteins is due to a significant increase in filtered load across the glomerular membrane (due to alterations in the permselectivity of the glomerular capillary wall) and from defects and/or saturation in the tubular reabsorption pathways. Many studies have evaluated the renal function changes with DM/DN using neutral dextrans or Ficoll probes [6, 67, 68, 74] . Significant increase in the filtration of the probes as well as proteins was observed, and the occurrence of proteinuria was attributed to the development of large pores in the GBM. This was accompanied by simultaneous changes in charge and size selectivity, which led to macroalbuminuria. Furthermore, as the filtered load increases with diabetes progression, the tubular reabsorption pathway becomes saturated. Some studies have also reported a decrease in the efficiency or dysfunction in the tubular reabsorption pathway. After endocytosis, excessive amounts of proteins can accumulate in the lysosomes of proximal tubule cells and can induce inflammation and fibrogenesis in the interstitium [32, 75, 76] .
We have recently evaluated the effect of T2DM and DN in Zucker diabetic fatty (ZDF) rats on the disposition of human IgG (hIgG), an antibody isotype, after its IVand subcutaneous (SC) administration [77••] . ZDF rats were treated with the anti-diabetic drug pioglitazone to evaluate the role of T2DM and DN on the pharmacokinetics of hIgG. The role of chronic kidney disease (CKD) was assessed using 5/6 nephrectomized Sprague Dawley rats. ZDF male control and obese diabetic rats and pioglitazone-treated diabetic ZDF rats were studied at ages 12-13 weeks (only DM was present) and at ages 29-30 weeks (progression to DN). ZDF rats had significantly higher blood glucose concentrations and urinary albumin excretion compared to control rats. With pioglitazone treatment, diabetic animals became euglycemic, although the changes in urinary albumin excretion were incompletely reversed.
Significant increases in the total clearance (2.5-fold) and renal clearance (100-fold) of hIgG were observed; however, the major increase in total clearance was due to increased nonrenal clearance. With the progression of the disease to DN, there were significant increases in urinary albumin excretion, as well as in the total and renal clearances of IgG (3.5-fold and 300-fold, respectively) (Fig. 4) . SC bioavailability of hIgG in all animal groups was high (>84 %) and unchanged among groups. Pioglitazone treatment in the diabetic animals was able to reverse the changes in total clearance. However, the changes in renal clearance were incompletely reversed, similar to the changes observed with urinary albumin excretion. In the experimental CKD animals, hIgG clearance was unchanged compared with controls. In conclusion, the effect of T2DM on hIgG renal and catabolic clearances was characterized by an increased clearance of hIgG in ZDF diabetic animals that could be reversed by pioglitazone treatment. CKD had no significant effect on hIgG clearance. Our studies suggest that there may be increased clearance of monoclonal antibodies in poorly controlled diabetic subjects that demonstrate hyperglycemia [77••] .
Mechanisms Involved in the Increased IgG and mAb Clearance in DM/DN

Altered Expression of FcRn, Megalin, and Cubilin
Different studies have reported a decrease in megalin function with DM and obesity. Impairment of megalin function, even in the early stages of diabetes, has been observed in rat animal models as well as in patients [78] [79] [80] . Streptozotocin-induced diabetic rats had decreased protein expression of megalin at the apical membrane of proximal convoluted tubule cells. Megalin expression can be severely down-regulated due to protein overload in diabetes, via activation of the reninangiotensin system and increased transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF-α) signaling in the lumen of the proximal tubular cells [80] . Treatment of diabetic rats with quinapril and candesartan (angiotensin converting enzyme inhibitors) restored the expression. Pioglitazone, at low doses, even without glycemic control, has been reported to normalize the renal concentrations of TNF-α and megalin [81] . Thus, impaired renal expression of megalin may not only inhibit the clearance of IgG antibodies from glomerular podocytes (thus causing local inflammation and glomerular damage) but also prevent the uptake and catabolism of IgG through the proximal tubule cells [61•] . Studies have observed decreased megalin mRNA expression in response to albumin overload in cell culture systems [82] . However, changes in megalin/cubilin expression with chronic kidney disease are controversial. Interestingly, certain studies with proteinuric mice did not observe any significant changes in megalin expression [83] . Megalin and cubilin may be regulated during nephrotic syndrome; effects might be associated with a decrease in expression to protect the proximal tubule from toxic accumulation or an increase in expression to fulfill their role as scavenger receptors [84] . Further studies evaluating the expression, activity, and regulation of megalin and cubilin may be able to shed more light on the changes associated with DM/DN in their pathways.
The relationship between FcRn and antibody catabolism is well documented in the literature; however, there is no information regarding FcRn expression or function in DM/DN. The location of FcRn on glomerular epithelial cells, where IgG-FcRn interactions in the renal podocytes result in clearance of IgG from the glomerular basement membrane, and in Fig. 4 a Plasma concentration-time profiles of human IgG in control, ZDF diabetic, and pioglitazone-treated ZDF rats after IVadministration of 1 mg/kg at 12-13 weeks of age (phase A) when only DM is present. b Total clearance and renal clearance as a fold change related to the control group after the administration of 1 mg/kg IgG to control, ZDF diabetic, and pioglitazone-treated ZDF rats at ages of 12-13 weeks (when only DM is present; phase A) and 26-28 weeks (when DM/DN is present; phase B). Asterisk: significant differences between phase A and phase B were determined by ANOVA with a Tukey's test, p < 0.05; n = 6-8 animals per group (data from Chadha and Morris [77••]) renal proximal tubule epithelial cells, where it may be involved in endocytosis at the apical membrane [55, 56] , suggest a role of FcRn in protein renal elimination. FcRndeficient mice have significantly higher urinary albumin excretion and lower serum concentrations, compared to control mice, and exhibit increased catabolism of IgG in tissues [85] . A study of familial hypercatabolic hypoproteinemia, which is a rare human syndrome, reported very low serum levels of IgG and albumin that correlated with abnormally low expression of FcRn, thus showing strong correlation between FcRn protein expression and albumin and IgG disposition [86] .
Non-Enzymatic Glycosylation of IgG
Chronic hyperglycemia in DM leads to non-enzymatic glycation of proteins or advanced protein glycosylation, and glycosylation of IgG has been demonstrated to be increased in DM/DN [87] [88] [89] . This process involves non-enzymatic modification of tissue proteins by physiologic sugars through which sugar molecules become covalently attached to amino groups on the lysine residues or the N-terminal amino acids of proteins to form a labile Schiff base [90] . This is followed by cross-linking of proteins, which leads to formation of advanced glycation end products (AGEs). These sugar-derived modification products play a significant role in the pathogenesis of diabetic complications, affecting renal function as well as tissue concentrations and metabolism [91] . Non-enzymatic modification of proteins causes alterations in charge, solubility, and conformation which lead to molecular dysfunction and disrupted interactions with other proteins [89, 92] . Hemoglobin, along with other proteins including IgG, IgA, IgM, and albumin, undergo glycosylation in patients with DM. A positive correlation has been clinically observed between glycosylated hemoglobin, glycosylated albumin, and glycosylated IgG [89, 93] . Around 10 % of the albumin in normal human serum can be glycosylated, which can cause a conformational change in human serum albumin and alter its functional properties [90] . Glycosylation of IgM leads to a significant decrease in its agglutination function, which could decrease the diabetic patient's resistance to infections [94] . Glycosylation of IgG from rabbit and human serum, as a result of in vitro glucose incubation, led to a marked decrease in the biological activity of IgG, as determined in a microcomplement fixation test. Furthermore, inactivation of the specific antibody was dependent on incubation time and glucose concentration used for the process [95] . Also, long-term incubations of IgG led to the formation of heavy molecular weight aggregates, suggesting an AGE-like process [96] . Glycated IgG has altered binding to protein A, which can cause increased phagocytic engulfment of the antibody [97] . The presence of high affinity receptors for AGE-proteins has been observed in mouse macrophages, suggesting macrophage degradation of antibody is an in vivo mechanism for the removal of the antibody [98] . A study in mice has demonstrated a significant increase in the vascular clearance rate of glycated IgG, as compared to unglycated IgG [88] .
In patients with DM, AGE-proteins are known to accumulate in glomerular basement membrane, mesangial cells, endothelial cells, and podocytes, resulting in the progression of DM to DN. Presence of AGE-proteins leads to increased oxidative stress and overproduction of different growth factors and cytokines [99] . This causes deterioration of the GBM endothelial layer and promotes podocyte cell detachment. Thus, the renal system becomes more susceptible to renal fibrosis, leading to increase in filtration of plasma proteins across GBM [89, 100, 101] . The renal function damage in DN by AGE can be reversed by pharmacological agents such as aminoguanidine, which reduces concentrations of AGEs. It significantly reduced urinary albumin elimination by around 90 % and slowed the progression of nephropathy [102, 103] . While increased glycosylation of IgG can occur in DM/DN, the role that this modified IgG plays in its increased clearance is unknown.
Hypercatabolism of Proteins
Under normal conditions, the fasting state in humans is characterized by release of glutamine and alanine from muscles and with the catabolism of branched chain amino acids (leucine, isoleucine, and valine) in muscle. This is associated with the replenishment of muscle nitrogen by the muscle uptake of branched chain amino acids in ingested protein. In diabetic patients, there is protein hypercatabolism, resulting in the increased uptake of alanine by the liver for gluconeogenesis and in accelerated branched chain amino acid breakdown in the muscles. There is reduced muscle uptake and concentrations of amino acids increase in the arterial blood. One of the primary reasons for this imbalance is due to the lack of insulin, which is prominent in T1DM. However, this hypercatabolism state is less frequent in T2DM where insulin stores are not compromised [104, 105] . However, exposure of tissues to chronic hyperglycemia acts as an initiating factor that can alter the metabolism state of the body by a number of potential mechanisms. Renal and non-renal cells are stimulated by hyperglycemia, which leads to over-activation and production of different cytokine factors that are responsible for structural and functional alterations in diabetes and DN. The metabolic changes include increase in reactive oxygen species and in inflammatory cytokines along with growth and apoptotic factors [106, 107] .
Role of Cytokines
Cytokines are a group of low molecular weight soluble proteins and peptides, and many studies have evaluated the role of cytokines in modulating the disposition of mAbs and IgG, via changes in FcRn expression. Studies have observed DM/ DN progression to be closely associated with elevation of levels of IL-6 [108] . TNF-α has also been observed to directly regulate the mRNA and protein expression of FcRn. TNF-α is a member of the inflammatory cytokine family [107] that can activate various second messenger pathways, transcription factors, growth factors, cell adhesion molecules, and enzymes involved in the synthesis of other inflammatory mediators. Many studies have reported a consistent increase in TNF-α mRNA and protein expression in glomerular and proximal tubule cells of diabetic rats [109] [110] [111] [112] . The increase in TNF-α led to a down-regulation of FcRn mRNA and protein expression in human retinal pigment epithelium cells [44] . However, TNF-α treatment of an intestinal epithelial cell line (macrophage-like THP-1) and of freshly isolated human monocytes resulted in the rapid up-regulation of FcRn gene expression. Treatment of TNF-stimulated THP-1 cells with a NF-kappaB specific inhibitor has resulted in down-regulation of mRNA and protein FcRn expression [113] . Based on the literature, it is not possible at this time to establish a correlation between the expression of TNF-α and FcRn regulation. TNF-α may have a differential role for stimulating or inhibiting FcRn pathways and modulating the disposition of antibodies. The role of cytokines in the regulation of the endocytosis proteins megalin and cubilin has not been defined, although with an increase in TGF-β and TNF-α signaling pathways, a downregulation in the megalin protein expression has been observed in the proximal tubular cells [80] . The immunosuppressive drug myophenolate mofetil and anti-inflammatory drug pentoxifylline, that inhibit the transcription of the TNF-α gene, can largely prevent the development of albuminuria and glomerular injury in experimental DN. In addition, pentoxifylline modulates the expression of IL-1β and IL-6. Infliximab, an anti-TNF-α mAb, has also been investigated and can decrease urinary albumin excretion in streptozotocin-treated rats, an animal model of type I DM [114] . Therefore, inflammatory cytokines may play a role in the changes in renal function and protein catabolism observed in DM/DN, or alternatively changes in inflammatory cytokine protein levels may be a consequence of changes in renal function or hyperglycemia.
Information Gap
The mechanisms underlying the increased renal and catabolic clearances of IgG and monoclonal antibodies in DM/DN are currently unknown but may involve changes in the expression of FcRn and the endocytic proteins megalin and cubilin, increased glycosylation of high molecular weight proteins, and effects due to increased cytokine plasma and tissue concentrations. The clinical significance of these findings is also not known, but considering the high incidence rate of DM and DN (~10 % of the American population) and their high association with co-morbidities (heart disease, retinopathy, neuropathy, transplantation), the use of mAbs in these populations is likely for various indications [115] [116] [117] and may result in decreased plasma concentrations of mAbs impacting the pharmacodynamics of the mAbs.
Conclusion
Although research has focused on characterizing the pathophysiology of diabetes and the pharmacological interventions for diabetes, very little information is available regarding the effect of the disease on the pharmacokinetics and pharmacodynamics of mAbs, including the influence of diabetes on the catabolic and renal clearances of higher molecular weight proteins. This review addresses this information gap and evaluates the effect of DM and DM/DN on the disposition and clearance of IgG, a monoclonal antibody isotype, and the potential mechanisms contributing to the alterations in clearance.
